Nanjing Leads Biolabs Co., Ltd. is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of innovative therapeutic antibodies. With a diversified pipeline, the company focuses on next-generation immunotherapies designed to address unmet medical needs in oncology, autoimmune diseases, and other major health conditions. Its research encompasses monoclonal antibodies, bispecific T-cell engagers, antibody-drug conjugates, and fusion proteins, reflecting a robust and technologically advanced portfolio. Nanjing Leads Biolabs is recognized for rapid advancement from early-stage discovery to investigational new drug applications, leveraging proprietary platforms such as LeadsBody™ for CD3 T-cell engagement and X-body™ for 4-1BB activation. The company has achieved key milestones, including securing U.S. FDA Orphan Drug Designation and Breakthrough Therapy recognition in China for several of its assets. Its integrated, science-driven approach allows for seamless progression from preclinical research through clinical trials, positioning Nanjing Leads Biolabs as an emerging leader in the development of transformative immunotherapies within the biopharmaceutical sector.